A retrospective analysis of practice patterns in the treatment of methicillin-resistant Staphylococcus aureus skin and soft tissue infections at three Canadian tertiary care centres

Canadian Journal of Infectious Diseases

Volumn 14, Issue 6, 2003, Pages 315-321

  Conly, John M ^a,f   Stiver, H Grant ^b   Weiss, Karl A ^c   Becker, Debbie L ^d   Rosner, Andrew J ^d   Miller, Elizabeth ^e  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^d i3 Global   (Canada)

^e Patient Access and Outcomes Research   (Canada)

^f CALGARY HEALTH REGION   (Canada)

Author keywords

Methicillin resistant Staphylococcus aureus; Switch therapy; Treatment patterns; Vancomycin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFAZOLIN; CEFOTETAN; CEFOXITIN; CIPROFLOXACIN; CLINDAMYCIN; CLOXACILLIN; DOXYCYCLINE; FLUCONAZOLE; IMIPENEM; LEVOFLOXACIN; LINEZOLID; METRONIDAZOLE; NETILMICIN; VANCOMYCIN;

ADULT; AGED; ARTICLE; CANADA; CLINICAL PRACTICE; DEMOGRAPHY; FEMALE; HEALTH CARE SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; SKIN INFECTION; SOFT TISSUE INFECTION; SURGICAL WOUND; TREATMENT PLANNING;

EID: 0442309632     PISSN: 11802332     EISSN: None     Source Type: Journal    
DOI: 10.1155/2003/103682     Document Type: Article

References (34)

1. Conly JM, Johnston BL. Antibiotic resistance in Canada at the dawn of the new millenium - a model for the developed world? Can J Infect Dis 2000;11:232-5.
2. Romero-Vivas J, Rubio M, Fernandez C, Picazo JJ. Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 1995;21:1417-23.
3. Holmberg SD, Solomon SL, Blake PA. Health and economic outcomes of antimicrobial resistance. Clin Infect Dis 1987;9:1065-78.
4. Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999;159:1127-32.
5. Kim T, Oh PI, Simor AW. The economic impact of methillin-resistant Staphylococcus aureus in Canadian hospitals. Infect Control Hosp Epidemiol 2001;22:99-104.
6. Low DE, Garcia M, Callery S, et al. Methicillin-resistant Staphylococcus aureus - Ontario. Canadian Disease Weekly Report 1981;7:249-50.
7. Conly J. Antimicrobial resistance in Canada. CMAJ 2002;167:885-91.
8. Taylor G, Kirkland T, Kowalewska-Grochowska K, Wang Y. A multistrain cluster of methicillin-resistant Staphylococcus aureus based in a native community. Can J Infect Dis 1990;1:121-6.
9. Embil J, Ramotar K, Romance R, et al. Methicillin-resistant Staphylococcus aureus in tertiary care institutions on the Canadian prairies 1990-1992. Infect Control Hosp Epidemiol 1994;15:646-51.
10. Berlet G, Richards RS, Roth JH. Clenched-fist injury complicated by methicillin-resistant Staphylococcus aureus. Can J Surg 1997;40:313-4.
11. Gardam MA. Is methicillin-resistant Staphylococcus aureus an emerging community pathogen? A review of the literature. Can J Infect Dis 2000;11:202-11.
12. Devlin HR. Bacteria for the nineties. Ostomy Wound Manage 1998;44:32-40.
13. Conly JM, Ofner ME, Paton S, et al. The emerging epidemiology of vancomycin-resistant enterococci in Canada 1993-1998: Results from the Canadian Nosocomial Infections Surveillance Program Passive Reporting Network. Can J Infect Dis 1999;10:38D. (Abst)
14. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997;350:1670-3.
15. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999;340:493-501.
16. Centers for Disease Control. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. MMWR Morb Mortal Wkly Rep 1997;46:813-5.
17. Simor AE, Ofner-Agostini MO, Bryce E, et al, and the CNISP. The evolution of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 5 years of national surveillance. CMAJ 2001;165:21-6.
18. Conly JM, Stiver GH, Weiss KA, et al. A survey of methicillin-resistant Staphylococcal species treatment patterns in Canada. Submitted to Can J Infect Dis.
19. Jewesson P. Cost-effectiveness and value of an IV switch. Pharmacoeconomics 1994;5(Suppl 2):20-6.
20. Zamin MT, Monique MP, Conly JM. Development of an intravenous-to-oral route conversion program for antimicrobial therapy at a Canadian tertiary care health facility. Ann Pharmacother 1997;31:564-70.
21. Rhew DC, Tu GS, Ofman J, Henning JM, Richards MS, Weingarten SR. Early switch and early discharge strategies in patients with community-acquired pneumonia. Arch Intern Med 2001;161:722-7.
22. Frighetto L, Nickoloff D, Martinusen SM, Mamdani FS, Jewesson PJ. Intravenous-to-oral stepdown program: Four years of experience in a large teaching hospital. Ann Pharmacother 1992;26:1447-51.
23. Paladino JA. Pharmacoeconomic comparison of sequential IV/oral ciprofloxacin versus ceftazidime in the treatment of nosocomial pneumonia. Can J Hosp Pharm 1995;48:276-83.
24. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000;283:749-55.
25. Omidvari K, de Boisblanc BP, Karam G, Nelson S, Haponik E, Summer W. Early transition to oral antibiotic therapy for community-acquired pneumonia: Duration of therapy, clinical outcomes, and cost analysis. Respir Med 1998;92:1032-9.
26. Hendrickson JR, North DS. Pharmacoeconomic benefit of antibiotic step-down therapy: Converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil. Ann Pharmacother 1995;29:561-5.
27. Siegal RE, Halpern NA, Almonoff PL, Lee A, Cashin R, Greene JG. A prospective randomized study of inpatient IV antibiotics for community-acquired pneumonia: The optimal duration of therapy. Chest 1996;110:965-71.
28. Dietrich ES, Joseph U, Vogel F, et al. Cost-effectiveness of ceftriaxone 1 g vs second-generation cephalosporins in the treatment of pneumonia in general medical wards in Germany. Infection 1999;27:148-54.
29. Rittenhouse BE, Stinnett AA, Dulisse B, et al. Evaluating the costs of levofloxacin and ceftriaxone in inpatient adults with community-acquired pneumonia. Pharm Ther 1999;24:169-79.
30. Dresser LD, Niederman MS, Paladino JA. Cost-effectiveness of gatifloxacin versus ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. Chest 2001;119:1439-48.
31. The Ontario Anti-Infective Review Panel. Anti-infective guidelines for community-acquired infections. 3rd edition. Toronto: Queen's Printer for Ontario, 2001.
32. Health and Welfare Canada. Canadian guidelines for the prevention, diagnosis, management and treatment of sexually transmitted diseases in neonates, children, adolescents and adults. Can Commun Dis Rep 1992;18:88-90.
33. STD treatment guidelines. 1992. **Ottawa?**: Government of Ontario, 1992.
34. Reese RE, Betts RF. A practical approach to infectious diseases. Toronto: Little, Brown & Company, 1991.